Recent Press Releases

Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs

– Christopher Garabedian Resigns as Chief Executive Officer and Member of the Board Effective Today –– Company will host conference call at 8:00 a.m. EDT, April 1, 2015 –...

Experimental cancer drug restores memory in mouse model of Alzheimer's

Star–like glial cells in red surround alpha beta plaques in the cortex of a mouse with a model of Alzheimer's Disease. Memory and as well as connections between brain cells were restored in...

PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services

BOSTON -- PAREXEL International Corporation (Nasdaq: PRXL), a global clinical research organization, announced today that the Company has signed a definitive agreement to acquire all of the business...

GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome

GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome London, UK, 31 March 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the...

Cerulean Announces Proposed Public Offering of Common Stock

Cerulean Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (Nasdaq: CERU) today announced that it has commenced an underwritten public...

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services Combines the complementary strengths and scale of leading biopharmaceutical services and...

Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease

Cambridge, Mass. March 31st, 2015 — The Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The...

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma WALTHAM, Mass. & KENILWORTH,...

Fujifilm Holdings to Acquire Cellular Dynamics International, Inc.

TOKYO and MADISON, Wis., March 30, 2015 /PRNewswire/ -- FUJIFILM Holdings Corporation (President: Shigehiro Nakajima,) (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, Inc....

Aegerion Pharmaceuticals Reaches Agreement With Sarissa Capital

CAMBRIDGE, Mass. -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating...

The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) and RAPLIXA™ (sealant powder)

Marketing authorization valid in 31 countries of the European Economic Area -- KENGREXAL™ is the first and only intravenous antiplatelet agent that provides immediate, consistent, and rapidly...

Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab

ZUG, Switzerland--Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade®1 as the reference product, has...

Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis

PETACH TIKVA, Israel, March 30, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and...

BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development

RALEIGH, N.C., March 30, 2015 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared...

Novan Secures $50 Million Private Financing

Funds Intended to Advance SB204 into Phase 3; Company Expands Board with the Addition of Three Directors DURHAM, N.C. (March 15, 2015) - Novan Therapeutics, a clinical-stage biotechnology company...

Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy

-- Chimeric Antigen Receptor T-cell (CAR-T) therapy enhances Merck Serono's R&D technology portfolio in immuno-oncology -- Collaboration and license agreement will focus on developing a next...

Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group

Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances the...

Teva Reinforces Leadership Position in CNS with Acquisition of Auspex

Expected to strengthen Teva's core CNS franchise, establish Teva's leadership in underserved movement disorders space, provide compelling new treatment options for patients in need, and enhance...

Novo Nordisk to Launch Novoeight® in the United States for People With Hemophilia A

PLAINSBORO, N.J. -- Novo Nordisk today announced the company will launch Novoeight®(Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight®...

Shire and Cincinnati Children's Establish Rare Disease Research Collaboration

LEXINGTON, Massachusetts and CINCINNATI, March 26, 2015 -- Shire plc (LSE: SHP, NASDAQ: SHPG) and Cincinnati Children's Hospital Medical Center today announced a three-year, broad research...